Association between use of HMG CoA reductase inhibitors and mortality in HIV-infected patients.
<h4>Introduction</h4>HIV infection is a disease associated with chronic inflammation and immune activation. Antiretroviral therapy reduces inflammation, but not to levels in comparable HIV-negative individuals. The HMG-coenzyme A reductase inhibitors (statins) inhibit several pro-inflamm...
Guardado en:
Autores principales: | Richard D Moore, John G Bartlett, Joel E Gallant |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/fe742c71792c49bb87a7e85458071084 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
HMG-CoA reductase inhibitors and COVID-19 mortality in Stockholm, Sweden: A registry-based cohort study.
por: Rita Bergqvist, et al.
Publicado: (2021) -
Exploration of virtual candidates for human HMG-CoA reductase inhibitors using pharmacophore modeling and molecular dynamics simulations.
por: Minky Son, et al.
Publicado: (2013) -
Discovery of a potent HMG-CoA reductase degrader that eliminates statin-induced reductase accumulation and lowers cholesterol
por: Shi-You Jiang, et al.
Publicado: (2018) -
A Possible Role for HMG-CoA Reductase Inhibitors and Its Association with <i>HMGCR</i> Genetic Variation in Parkinson’s Disease
por: Anna Pierzchlińska, et al.
Publicado: (2021) -
Rac1-regulated endothelial radiation response stimulates extravasation and metastasis that can be blocked by HMG-CoA reductase inhibitors.
por: Melanie Hamalukic, et al.
Publicado: (2011)